Elevance Health, Inc. $ELV Holdings Raised by High Ground Investment Management LLP

High Ground Investment Management LLP grew its stake in Elevance Health, Inc. (NYSE:ELV) by 19.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 289,232 shares of the company’s stock after buying an additional 46,390 shares during the quarter. Elevance Health accounts for approximately 15.5% of High Ground Investment Management LLP’s portfolio, making the stock its 3rd biggest position. High Ground Investment Management LLP owned approximately 0.13% of Elevance Health worth $93,457,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in ELV. Physician Wealth Advisors Inc. grew its holdings in Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares in the last quarter. Activest Wealth Management lifted its position in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its stake in shares of Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. purchased a new position in Elevance Health in the second quarter valued at $32,000. Finally, Motco raised its stake in Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Price Performance

Shares of NYSE ELV opened at $340.34 on Thursday. The stock has a market cap of $75.64 billion, a P/E ratio of 13.55, a P/E/G ratio of 1.89 and a beta of 0.50. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The stock has a 50 day moving average of $352.02 and a two-hundred day moving average of $329.67. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s dividend payout ratio is currently 27.23%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ELV. Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Wolfe Research set a $425.00 price target on Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Weiss Ratings cut shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday. Wells Fargo & Company reduced their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Finally, UBS Group set a $400.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.